Immunological analyses from the FORTE trial that compared 20 versus 40 mg dose of glatiramer acetate in multiple sclerosis

被引：0
作者：
Yong, V. W.
Verhaeghe, B.
Silva, C.
Myles, M. L.
Metz, L.
机构：
[1] Hotchkiss Brain Inst, Calgary, AB, Canada
[2] Univ Alberta, Edmonton, AB, Canada
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S239 / S239
页数：1
相关论文
共 50 条
  • [21] Effect of Switching Glatiramer Acetate Formulation from 20 mg Daily to 40 mg Three Times Weekly on Immune Functions in RRMS
    Ito, K.
    Ito, N.
    Yadav, S.
    Suresh, S.
    Lin, Y.
    Dhib-Jalbut, S.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 45 - 45
  • [22] High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial)
    Dhooria, Sahajal
    Sehgal, Inderpaul Singh
    Agarwal, Ritesh
    Muthu, Valliappan
    Prasad, Kuruswamy Thurai
    Dogra, Pooja
    Debi, Uma
    Garg, Mandeep
    Bal, Amanjit
    Gupta, Nalini
    Aggarwal, Ashutosh Nath
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62 (03)
  • [23] Gene Expression Profiles Following One-Year Treatment with Glatiramer Acetate 20mg and 40mg (GA, Copaxone®) in Relapsing-Remitting Multiple Sclerosis Patients
    Achiron, Anat
    Belker, Tal
    Yemini, Einav
    Sonis, Polina
    Gurevich, Michael
    [J]. NEUROLOGY, 2009, 72 (11) : A38 - A39
  • [24] A Comparative Placebo-Controlled Clinical Trial of the Efficacy and Safety of Glatiramer Acetate 20 mg in Patients with Remitting Multiple Sclerosis: First-Year Study Results
    Boiko A.N.
    Lashch N.Y.
    Sharanova S.N.
    Zakharova M.N.
    Trifonova O.V.
    Simaniv T.O.
    Lysogorskaya E.V.
    Gur’yanova O.E.
    Kotov S.V.
    Yakushina T.I.
    Lizhdvoi V.Y.
    Belova Y.A.
    Khabirov F.A.
    Babicheva N.N.
    Khaibullin T.I.
    Granatov E.V.
    Aver’yanova L.A.
    Sazonov D.V.
    Odinak M.M.
    Trinitatskii Y.V.
    Tsukurova L.A.
    Sergeeva A.I.
    Ivanov R.A.
    Shustova M.S.
    [J]. Neuroscience and Behavioral Physiology, 2018, 48 (3) : 351 - 357
  • [25] Effect of switching from daily injections of 20mg glatiramer acetate to 40mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis over 33 months
    Hagemeier, Jesper
    Weinstock-Guttman, Bianca
    Bergsland, Niels
    Ramasamy, Deepa
    Durfee, Jacqueline
    Cherneva, Maryia
    Carl, Ellen
    Carl, Jillian
    Koib, Channa
    Hojnacki, David
    Zivadinov, Robert
    [J]. NEUROLOGY, 2017, 88
  • [26] COPTIMIZE: a two-year observational survey of patients with relapsing remitting multiple sclerosis switching to glatiramer acetate 20 mg daily
    Ziemssen, T.
    Bajenaru, O.
    Carra, A.
    de Klippel, N.
    de Sa, J.
    Edland, A.
    Frederiksen, J.
    Heinzlef, O.
    Karageorgiou, K.
    Landtblom, A. M.
    Macias Islas, M.
    Tubridy, N.
    Gilgun-Sherki, Y.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 444 - 445
  • [27] A phase 3 trial to assess the efficacy and safety of glatiramer acetate injections 40mg administered 3 times a week compared to placebo
    Khan, O.
    Rieckmann, P.
    Boyko, A.
    Selmaj, K.
    Zivadinov, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 512 - 512
  • [28] CONFIDENCE: Phase IV study to evaluate medication satisfaction with glatiramer acetate 40mg/ml three-times weekly versus once-daily glatiramer acetate 20mg/ml in patients with RRMS
    Grinspan, A.
    Gandhi, S. K.
    Cutter, G. R.
    Copetti, M.
    Kormann, D.
    Veneziano, A.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 671 - 671
  • [29] RCT Abstract - High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial)
    Dhooria, Sahajal
    Sehgal, Inderpaul Singh
    Agarwal, Ritesh
    Prasad, Kuruswamy Thurai
    Aggarwal, Ashutosh Nath
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [30] Higher medication satisfaction and treatment adherence in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate 40 mg/ml three-times weekly compared with 20 mg/ml daily: 6-month results of the CONFIDENCE study
    Veneziano, A.
    Cutter, G.
    Al-Banna, M.
    Rossi, S.
    Zakharova, M.
    Boyko, A.
    Gandhi, S.
    Everts, R.
    Grinspan, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 641 - 642
12345